Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM4JCA)

Drug Name
HG-1051 Drug Info
Synonyms
CD136 modulator (inflammation/immune disorders), Human Genome Sciences; CD137 antigen modulator (inflammation/immune disorders), Human Genome Sciences; CDw137 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse Ly63 modulator (inflammation/immune disorders), Human Genome Sciences; ILA modulator (inflammation/immune disorders), Human Genome Sciences; MGC2172 modulator (inflammation/immune disorders), Human Genome Sciences; T cell antigen ILA modulator (inflammation/immune disorders), Human Genome Sciences; TNFRSF9 modulator (inflammation/immune disorders), Human Genome Sciences; Tumor necrosis factor receptor superfamily member 9 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences; Human 4-1BB receptor splicing varifant modulator (inflammation/immune disorders), Human Genome Sciences; Induced by lymphocyte activation (ILA) modulator (inflammation/immune disorders), Human Genome Sciences; Interleukin-activated receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB ligand receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences
Indication
Disease Entry ICD 11 Status REF
Immune System disease 4A01-4B41 Investigative [1]
Cross-matching ID
TTD Drug ID
DMM4JCA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Urelumab DM6RTVG B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [2]
Anti-CD137 DMHVZ27 Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
MG7-CART DME6PB0 Acute myeloid leukaemia 2A60 Phase 1/2 [3]
NM21-1480 DMDNJP5 Advanced solid tumour 2A00-2F9Z Phase 1/2 [4]
CD137 CAR-T Cell DMHMC19 Acute lymphoblastic leukaemia 2A85 Phase 1/2 [5]
ADG106 DM87H0S Non-hodgkin lymphoma 2B33.5 Phase 1/2 [6]
CD28 and CD137 CAR-T Cells DMFGQXB Acute lymphoblastic leukaemia 2A85 Phase 1 [7]
MCLA-145 DM8CGUV Lymphoma 2A80-2A86 Phase 1 [8]
GEN1046 DMEWRNZ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
INBRX-105 DM2FH10 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Co-stimulatory molecule 4-1BB (CD137) TTPW9LJ TNR9_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
4 Clinical pipeline report, company report or official report of Numab Therapeutics.
5 ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
6 Clinical pipeline report, company report or official report of Adagene.
7 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
8 Clinical pipeline report, company report or official report of Merus.
9 Clinical pipeline report, company report or official report of Genmab.
10 Clinical pipeline report, company report or official report of Inhibrx.